Binah-David Institute of Chemistry

My company, Binah-David Institute of Chemistry, has the mission to develop novel anti-cancer agents. The medical and scientific literature has shown that thyroid hormone is 
a  promoter of cancer growth, angiogenesis and tumor metastasis.  The medical literature has examples of patients with significant hypothyroidism who have had regression of their 
cancers such as lung and breast cancers  in the hypothyroid state. Researchers have discovered the integrin receptor Avbeta3, which is located on the cell surface of certain 
cancers such as lung, breast, renal and pancreas. This receptor bind the hormone L-thyroxine synthesized by the thyroid gland  and this hormone promotes cancer growth. 
The analogue tetraiodothyroacetic acid  which is the deaminated chemical analogue of thyroid hormone, binds to the Avbeta3  receptor and inhibits tumor growth.
The goal of my company is to synthesize novel fluorinated analogues of tetraiodothyroacetic acid  and evaluate their anticancer activity against tumors harboring the AvBeta3 receptor.
It has been shown that many synthetic organic compounds with the fluorine atom incorporated have increased biological activity.  Currently, 20% of all pharmaceuticals has a fluorine atom incorporated  in the molecular structure.  I will be synthesizing the fluorinated analogue  tetrafluorothyroacetic acid and evaluating this novel compound's activity towards 
cancers that harbor the Avbeta3 receptor.

My credentials include having a  Phd in Organic Chemistry with post-doctoral training in Medicinal Chemistry at Memorial Sloan-Kettering Cancer Institute. 
I also am  physician  with  Board Certification in Endocrinology with a special focus on thyroid disease and thyroid cancer. 

I would certainly enjoy giving you a detailed PowerPoint presentation of my research  proposal for this innovative work and potential development of a novel anti-cancer agent.

James A Warshaw PhD. MD